15,525 Shares in Supernus Pharmaceuticals, Inc. $SUPN Bought by AdvisorShares Investments LLC

AdvisorShares Investments LLC bought a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 15,525 shares of the specialty pharmaceutical company’s stock, valued at approximately $742,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of SUPN. Hantz Financial Services Inc. lifted its holdings in shares of Supernus Pharmaceuticals by 81.7% in the 3rd quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock valued at $30,000 after purchasing an additional 281 shares during the last quarter. USA Financial Formulas purchased a new stake in shares of Supernus Pharmaceuticals during the third quarter worth approximately $50,000. Smartleaf Asset Management LLC raised its position in Supernus Pharmaceuticals by 30.8% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company’s stock worth $54,000 after buying an additional 268 shares during the last quarter. State of Wyoming purchased a new position in Supernus Pharmaceuticals during the third quarter worth about $68,000. Finally, EverSource Wealth Advisors LLC acquired a new position in Supernus Pharmaceuticals during the 2nd quarter worth approximately $51,000.

Supernus Pharmaceuticals Stock Up 4.6%

Shares of NASDAQ SUPN opened at $51.65 on Friday. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $29.16 and a fifty-two week high of $57.65. The firm has a market cap of $2.96 billion, a PE ratio of -151.91, a price-to-earnings-growth ratio of 0.65 and a beta of 0.71. The business has a 50 day moving average price of $49.12 and a two-hundred day moving average price of $46.76.

Insider Activity

In related news, VP Padmanabh P. Bhatt sold 710 shares of the firm’s stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $44.44, for a total transaction of $31,552.40. Following the transaction, the vice president directly owned 14,508 shares in the company, valued at $644,735.52. This trade represents a 4.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Frank Mottola sold 20,000 shares of the firm’s stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $50.41, for a total transaction of $1,008,200.00. Following the completion of the transaction, the senior vice president owned 15,496 shares in the company, valued at approximately $781,153.36. The trade was a 56.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 8.80% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

SUPN has been the topic of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Monday, December 29th. TD Cowen upped their target price on Supernus Pharmaceuticals from $45.00 to $60.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. Bank of America assumed coverage on shares of Supernus Pharmaceuticals in a research note on Wednesday, October 29th. They set a “buy” rating and a $65.00 price target on the stock. Stifel Nicolaus upped their target price on Supernus Pharmaceuticals from $50.00 to $55.00 and gave the company a “hold” rating in a research note on Friday, December 19th. Finally, Wall Street Zen lowered shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 31st. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Supernus Pharmaceuticals has an average rating of “Hold” and an average price target of $61.60.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.